Global biopharmaceutical major Merck (MSD outside the US and Canada) has unveiled promising Phase 3 data for enlicitide decanoate, its investigational once-daily oral PCSK9 inhibitor, positioning the therapy as a potentially transformative option in lipid management and cardiovascular disease (CVD) prevention.

The findings — presented as late-breaking science at the American Heart Association (AHA) Scientific Sessions 2025 — show that enlicitide achieved a statistically significant and clinically meaningful LDL-C reduction of up to 59.7% at 24 weeks compared to placebo. The investigational therapy also demonstrated sustained lipid lowering at one year, reinforcing its potential as the first oral PCSK9 molecule to deliver antibody-like efficacy with a safety profile comparable to placebo.

A Potential Shift in ASCVD Management

The CORALreef Lipids trial enrolled adults with or at risk of atherosclerotic cardiovascular disease (ASCVD) who were either on background lipid-lowering therapies or unable to tolerate statins. The study recorded:

• 55.8% LDL-C reduction at week 24 (primary analysis)
• 59.7% LDL-C reduction at week 24 (post-hoc reanalysis)
• Up to 52.4% sustained LDL-C reduction at one year
• Significant reductions in non-HDL-C (53.4%), ApoB (50.3%), and Lp(a) (28.2%)
• 67.5% of patients achieved≥50% LDL-C reduction and LDL-C <55 mg/dL at week 24, compared to 1.2% in the placebo arm

Importantly, adherence levels were exceptionally high at 97%, underscoring the potential advantage of a daily oral regimen over currently available injectable PCSK9 inhibitors.

Placebo-Like Safety With Strong Efficacy

Safety outcomes were comparable between treatment and placebo groups, with no significant differences in adverse events, serious adverse events, or deaths. Discontinuations due to adverse events remained low (3.1% for enlicitide vs. 4.1% for placebo).

Industry Implications: A New Frontier for PCSK9 Therapies

If approved, enlicitide could become the first-in-class oral PCSK9 inhibitor, expanding options for millions of patients globally who require aggressive LDL-C lowering but struggle with injectable therapies, adherence challenges, or statin intolerance.

For the Indian pharmaceutical industry, this development signals:

• A competitive opportunity to innovate in macrocyclic peptide design, a platform Merck leveraged for enlicitide
• Growing commercial potential in oral biologics-mimetic therapies
• Advancement of precision cardiovascular treatment pathways, an area of rising global and domestic demand

Also read: Gavi–UNICEF Deal Paves Way for Wider Access to R21/Matrix-M Malaria Vaccine

Moving Forward 

Merck plans to share data from the CORALreef Lipids trial — along with results from CORALreef HeFH and CORALreef AddOn studies — with regulatory agencies worldwide. The company emphasised its continued focus on improving ASCVD outcomes, aligning with global public health priorities as cardiovascular disease remains the leading cause of mortality worldwide.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!